Navigation Links
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate license agreement.

"The breadth of applications for Vical's gene delivery technology continues to grow, and now encompasses vaccine candidates against infectious diseases and cancer, cancer immunotherapies, and gene-based angiogenesis for cardiovascular diseases," said Vijay B. Samant, Vical's President and Chief Executive Officer. "We are pleased that our long-standing partner Merck is expanding to a second clinical-stage evaluation of our technology in the cancer area."

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015  Mytrus, a technology and services company revolutionizing clinical trials, ... consent has received approval for use by ... the first time e-Consent technology will be used in ... Mytrus was also the first electronic informed ... by the U.S. Food and Drug Administration in 2011. ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... company serving the pharmaceutical, biotechnology, and medical ... and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., ... the Japan PMDA for the manufacture of ... drug in July. STA is now the ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2
... China, Oct. 30 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a developer,and leading distributor of ... nutritional and dietary supplements,and medical devices and ... subsidiary in China, Konzern Pharmaceuticals, it has ...
... TAIPEI, Taiwan, Oct. 30 /PRNewswire-Asia/ -- ... from bench to bedside and community, Microlife is ... solution entails a series of,innovative professional blood pressure ... treatment follow-up. Microlife successfully,developed several physician-guided blood ...
Cached Medicine Technology:China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 4Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 2Microlife-WatchBP Series is Proud to Present its Total Concept at the World Hypertension Congress 3
(Date:8/28/2015)... ... August 28, 2015 , ... ... the top 5 millionaire dating sites . According to the listings, ... second best in this category. , A spokesperson of Top5MillionaireDatingSites.com said, ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known ... Clinic is now selling External Counterpulsation (EECP or ECP) machines with a full clinic ... has been in business since 2007 helping people prevent and reverse heart disease ...
(Date:8/28/2015)... MO (PRWEB) , ... August 28, 2015 , ... ... testosterone lawsuits now consolidated as MDL 2545, Testosterone Replacement Therapy Products ... a cap on the number of custodial files the PSC may receive for ...
(Date:8/28/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... be taken in order to ease the stress on the atmosphere, and lessen the ... understand fully the real cause of global warming and urges them to look into ...
(Date:8/28/2015)... ... , ... A complimentary webinar offered by healthcare consulting and accounting firm PYA ... to mandate bundled payments through the Comprehensive Care for Joint Replacement Program ... for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September 2, 2015. ...
Breaking Medicine News(10 mins):Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... NIDCR have created an animal model that mimics ... and dentin dysplasia. Dr. Ashok Kulkarni and his ... of TGF-b1 (transforming growth factor beta-1) in their ... defects, but at two weeks their teeth became ...
... is no longer an exclusively Western problem. Researchers ... threat to people in developing nations, particularly children. ... the biggest threats to the health of poor ... urbanisation, technology, food processing and even leisure time ...
... Board of Examinations has decided to conduct tests for any ... in the country, to ensure a higher standards amongst doctors, ... next month official sources said today. , ... the Indian Gazzette yesterday, specify that students who want to ...
... are more likely to develop heart failure A connection between depression ... researchers at Emory University School of Medicine in the US have ... from heart failure. ,The study included 2000 participants - ... over five per cent of the men and nine per cent ...
... a dash and sprinkel away: Researchers with the U.S. ... to making food tastier, are an abundant source of ... a balanced diet.Herbs have higher antioxidant activity than frutis, ... Their findings appear in the Journal of Agricultural and ...
... with arginine and vitamins increased the exercise capacity and quality ... acid// that can produce the gas nitric oxide which, in ... might think that arginine might help people with heart problems, ... heart. ,In fact the validation for arginine supplements ...
Cached Medicine News:Health News:Heriditary dental disorders 2Health News:Herbs: rich soure of antioxidants 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: